Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum

Clinical Biochemistry

Volumn 46, Issue 6, 2013, Pages 399-410

  Krastins, Bryan ^a   Prakash, Amol ^a   Sarracino, David A ^a   Nedelkov, Dobrin ^a   Niederkofler, Eric E ^a   Kiernan, Urban A ^a   Nelson, Randall ^b   Vogelsang, Maryann S ^a   Vadali, Gouri ^a   Garces, Alejandra ^a   Sutton, Jennifer N ^a   Peterman, Scott ^a   Byram, Gregory ^a   Darbouret, Bruno ^c   Pérusse, Joëlle R ^d   Seidah, Nabil G ^d   Coulombe, Benoit ^d   Gobom, Johan ^e   Portelius, Erik ^e   Pannee, Josef ^e   Blennow, Kaj ^e   Kulasingam, Vathany ^f   Couchman, Lewis ^g   Moniz, Caje ^g   Lopez, Mary F ^a   more..

^a Thermo Fisher Scientific   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c THERMO FISHER SCIENTIFIC   (Germany)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Clinical proteomics; Immunoassay; Mass spectrometry; Proteomics; SRM assay

Indexed keywords

PARATHYROID HORMONE; PROTEIN; SOMATOMEDIN C; DIAGNOSTIC AGENT; PLASMA PROTEIN;

ACCURACY; ALKYLATION; ARTICLE; CHROMATOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LIMIT OF DETECTION; MASS SPECTROMETRY; PLASMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE ASSAY; REDUCTION; SERUM; ALZHEIMER DISEASE; BLOOD; CARDIOVASCULAR DISEASE; GROWTH DISORDER; ISOLATION AND PURIFICATION; KIDNEY FAILURE; METHODOLOGY; NEOPLASM; DIAGNOSTIC USE; PROCEDURES;

ALZHEIMER DISEASE; BLOOD PROTEINS; CARDIOVASCULAR DISEASES; GROWTH DISORDERS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOASSAY; MASS SPECTROMETRY; NEOPLASMS; RENAL INSUFFICIENCY;

EID: 84891675858     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.12.019     Document Type: Article

References (60)

1. Hoofnagle A.N., Wener M.H. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009, 347:3-11.
2. Sapin R. Interferences in immunoassays: mechanisms and outcomes in endocrinology. Ann Endocrinol (Paris) 2008, 69:415-425.
3. Klee G.G. Interferences in hormone immunoassays. Clin Lab Med 2004, 24:1-18.
4. Wolthuis A. Impact of disease on interferences in blood bioanalysis. Bioanalysis 2011, 3:2223-2231.
5. Nedelkov D. Population proteomics: investigation of protein diversity in human populations. Proteomics Feb 2008, 8(4):779-786. 10.1002/pmic.200700501.
6. Fu Q., Schoenhoff F.S., Savage W.J., Zhang P., Van Eyk J.E. Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin Appl 2010, 4:271-284.
7. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56:177-185.
8. Boja E.S., Rodriguez H. Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics 2012, 12:1093-1110.
9. Nedelkov D. Mass spectrometry-based protein assays for in vitro diagnostic testing. Expert Rev Mol Diagn 2012, 12:235-239.
10. Rauh M. LC-MS/MS for protein and peptide quantification in clinical chemistry. J Chromatogr B Analyt Technol Biomed Life Sci 2012, 883-884:59-67.
11. Hoofnagle A.N., Becker J.O., Oda M.N., Cavigiolio G., Mayer P., Vaisar T. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin Chem 2012, 58:777-781.
12. Prakash A., Rezai T., Krastins B., Sarracino D., Athanas M., Russo P., et al. Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J Proteome Res 2010, 9:6678-6688.
13. Prakash A., Rezai T., Krastins B., Sarracino D., Athanas M., Russo P., et al. Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J Proteome Res 2012, 11:3986-3995.
14. Addona T.A., Abbatiello S.E., Schilling B., Skates S.J., Mani D.R., Bunk D.M., et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641.
15. Becker J.O., Hoofnagle A.N. Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS. Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS. Bioanalysis 2012, 4:281-290.
16. Liotta L.A., Petricoin E.F. Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit. Clin Chem 2010, 56:1641-1642.
17. Longo C., Gambara G., Espina V., Luchini A., Bishop B., Patanarut A.S., et al. A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Exp Dermatol 2011, 20:29-34.
18. Shi T., Su D., Liu T., Tang K., Camp D.G., Qian W.J., et al. Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics 2012, 12:1074-1092.
19. Batalha I.L., Lowe C.R., Roque A.C. Platforms for enrichment of phosphorylated proteins and peptides in proteomics. Trends Biotechnol 2012, 30:100-110.
20. Thomas A., Schänzer W., Delahaut P., Thevis M. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls. Methods 2012, 56:230-235.
21. Ackermann B.L., Berna M.J. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 2007, 4:175-186.
22. Callesen A.K., Madsen J.S., Vach W., Kruse T.A., Mogensen O., Jensen O.N. Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool?. Proteomics 2009, 9:1428-1441.
23. Patel B.B., Barrero C.A., Braverman A., Kim P.D., Jones K.A., Chen D.E., et al. Assessment of two immunodepletion methods: off-target effects and variations in immunodepletion efficiency may confound plasma proteomics. J Proteome Res Dec 7 2012, 11(12):5947-5958. 10.1021/pr300686k.
24. Anderson N.L., Jackson A., Smith D., Hardie D., Borchers C., Pearson T.W. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 2009, 8:995-1005.
25. Nedelkov D. Population proteomics: addressing protein diversity in humans. Expert Rev Proteomics 2005, 2:315-324.
26. Nedelkov D., Phillips D.A., Tubbs K.A., Nelson R.W. Investigation of human protein variants and their frequency in the general population. Mol Cell Proteomics 2007, 6:1183-1187.
27. Saudek C.D., Brick J.C., Trenchevska O., Nedelkov D. Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci. 2011, 9:19.
28. Trenchevska O., Kamcheva E., Nedelkov D. Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J Proteome Res 2010, 9:5969-5973.
29. Oran P.E., Jarvis J.W., Borges C.R., Sherma N.D., Nelson R.W. Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteomics Clin Appl 2011, 5:454-459.
30. Borges C.R., Oran P.E., Buddi S., Jarvis J.W., Schaab M.R., Rehder D.S., et al. Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity. Clin Chem 2011, 57:719-728.
31. Weiss N.G., Jarvis J.W., Nelson R.W., Hayes M.A. Examining serum amyloid P component microheterogeneity using capillary isoelectric focusing and MALDI-MS. Proteomics 2011, 11:106-113.
32. Oran P.E., Jarvis J.W., Borges C.R., Nelson R.W. C-peptide microheterogeneity in type 2 diabetes populations. Proteomics Clin Appl 2010, 4:106-111.
33. Oran P.E., Sherma N.D., Borges C.R., Jarvis J.W., Nelson R.W. Intrapersonal and populational heterogeneity of the chemokine RANTES. Clin Chem 2010, 56:1432-1441.
34. Prensner J.R., Rubin M.A., Wei J.T., Chinnaiyan A.M. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012, 24:127rv3.
35. Lumen N., Fonteyne V., De Meerleer G., De Visschere P., Ost P., Oosterlinck W., et al. Screening and early diagnosis of prostate cancer: an update. Acta Clin Belg 2012, 67:270-275.
36. Carter H.B. Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl 2012, 14:355-360. 10.1038/aja.2011.141.
37. Lopez M.F., Rezai T., Sarracino D.A., Prakash A., Krastins B., Athanas M., et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010, 56:281-290.
38. Nelson R.W., Krone J.R., Bieber A.L., Williams P. Mass-spectrometric immunoassay. Anal Chem 1995, 67:1153-1158.
39. Pannee J., Portelius E., Oppermann M., Atkins A., Hornshaw M., Zegers I., et al. A Selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J Alzheimers Dis Jan 1 2013, 33(4):1021-1032. 10.3233/JAD-2012-121471.
40. Watt A.D., Perez K.A., Rembach A.R., Masters C.L., Villemagne V.L., Barnham K.J. Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. J Alzheimers Dis 2012, 30:323-336.
41. Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes 2012, 19:47-52.
42. Di Napoli M., Elkind M.S., Godoy D.A., Singh P., Papa F., Popa-Wagner A. Role of C-reactive protein in cerebrovascular disease: a critical review. Expert Rev Cardiovasc Ther 2011, 9:1565-1584.
43. Windgassen E.B., Funtowicz L., Lunsford T.N., Harris L.A., Mulvagh S.L. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med 2011, 123:114-119.
44. Clemmons D.R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 2011, 57:555-559.
45. Chauhan V., Kelepouris E., Chauhan N., Vaid M. Current concepts and management strategies in chronic kidney disease-mineral and bone disorder. South Med J 2012, 105:479-485.
46. D'Amour P. Circulating PTH, molecular forms: what we know and what we don't. Kidney Int Suppl Jul 2006, 102:S29-S33.
47. Scillitani A., Guarnieri V., Battista C., Chiodini I., Salcuni A.S., Minisola S., et al. Carboxyl-terminal parathyroid hormone fragments: biologic effects. J Endocrinol Invest 2011, 34:23-26.
48. Reichel C. Recent developments in doping testing for erythropoietin. Anal Bioanal Chem 2011, 401:463-481.
49. Duranton F., Cohen G., De Smet R., Rodriguez M., Jankowski J., Vanholder R., Argiles A. European uremic normal and pathologic concentrations of uremic toxins. Toxin work group. J Am Soc Nephrol 2012, 23:1258-1270.
50. Besler C., Lüscher T.F., Landmesser U. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 2012, 4:251-268.
51. Agger S.A., Marney L.C., Hoofnagle A.N. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple-reaction-monitoring mass spectrometry. Clin Chem 2010, 56:1804-1813.
52. Lassman M.E., McLaughlin T.M., Somers E.P., Stefanni A.C., Chen Z., Murphy B.A., et al. A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2012, 26:101-108.
53. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 2012, 73:221-227.
54. López-Miranda J., Pérez-Martínez P., Marín C., Moreno J.A., Gómez P., Pérez-Jiménez F. Postprandial lipoprotein metabolism, genes and risk of cardiovascular disease. Curr Opin Lipidol 2006, 17:132-138.
55. Lopez M.F., Sarracino D.A., Prakash A., Athanas M., Krastins B., Rezai T., et al. Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm. Proteomics Clin Appl 2012, 6:190-200.
56. D'Amour P. Acute and chronic regulation of circulating PTH: significance in health and in disease. Clin Biochem 2012, 45:964-969.
57. Scillitani A., Guarnieri V., Battista C., Chiodini I., Salcuni A.S., Minisola S., et al. Carboxyl-terminal parathyroid hormone fragments: biologic effects. J Endocrinol Invest 2011, 34:23-26.
58. Anderson N.L., Anderson N.G., Haines L.R., Hardie D.B., Olafson R.W., Pearson T.W. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004, 3:235-244.
59. Razavi M., Frick L.E., Lamarr W.A., Pope M.E., Miller C.A., Anderson N.L., et al. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J Proteome Res Dec 7 2012, 11(12):5642-5649. 10.1021/pr300652v.
60. Fornelli L., Damoc E., Thomas P.M., Kelleher N.L., Aizikov K., Denisov E., et al. Top-down analysis of monoclonal antibody IgG1 by electron transfer dissociation Orbitrap FTMS. Mol Cell Proteomics Dec 2012, 11(12):1758-1767. 10.1074/mcp.M112.019620.